3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Recruiting
1
Completed
1
Sponsor Class
OTHER_GOV
1
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Cognitive Dysfunction
1
Chemotherapy-Related Cognitive Impairment
1
Interventions
Cisplatin
352
Oxaliplatin
262
Capecitabine
258
Radiotherapy
240
Gemcitabine
223
Docetaxel
223
Carboplatin
223
Drug Therapy
219
Cyclophosphamide
219
Paclitaxel
205
apatinib
201
Bevacizumab
196
camrelizumab
190
Fluorouracil
188
sintilimab
133
Irinotecan
125
Blood Specimen Collection
125
Dexamethasone
123
Etoposide
119
Radiosurgery
118
toripalimab
117
Surgical Procedures, Operative
115
pembrolizumab
112
Pemetrexed
108
anlotinib
105
S 1 (combination)
105
Leucovorin
102
Surveys and Questionnaires
101
Nivolumab
98
tislelizumab
96
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
OTHER
×
Ashwagandha
×
Clear all
NCT04092647
2023-06-15
Ashwagandha for Cognitive Dysfunction
Sutter Health
Phase 2
Unknown
80 enrolled